Claims

1. A solid tablet that is directly-compressed of powder, comprising meloxicam or a pharmaceutically acceptable salt thereof and one or more excipients, characterised in that the directly-compressed powder was not subjected to a granulation step, in that the directly-compressed powder was screened through a suitable mesh having a mesh size of 600 µm to 1500 µm and contains meloxicam particles with a particle size of equal to and less than the selected mesh size~~in that the tablets have a diameter ranging from 10 mm to 20 mm and a height ranging from 5 mm to 7 mm, in that meloxicam is homogenously dispersed within the tablet~~, and in that the tablet can be broken into two, three and/or four units with each unit containing equal amounts of the active ingredient.

2. ~~A~~ The solid tablet according to claim 1, characterised in that the mesh has a mesh size of ~~800~~ 1000 µm to 1500 µm.

~~3. A tablet according to any of claims 1 to 2, characterised in that the directly-compressed powder contains particles with a particle size of equal to and less than the selected mesh size.~~

3. The solid tablet according to any of claims 1 to 2, characterised in that meloxicam is homogenously dispersed within the tablet.

4. ~~A~~ The soild tablet according to any of claims 1 to 3, characterised in that the excipients are selected from the group consisting of fillers, disintegrants, pH adjusters, colourants, flow regulator, lubricants and flavour.

5. ~~A~~ The soild tablet according to any of claims 1 to 4, characterised in that at least one of the excipients is a filler/disintegrant selected from the group consisting of calcium phosphate, lactose, maltodextrine, mannit, sorbit, cross-linked polyvinyl pyrrolidon, sodium carboxymethyl cellulose, starch and microcristalline cellulose.

6. ~~A~~ The soild tablet according to any of claims 1 to 5, characterised in that the colourants are ferric oxide brown and/or ferric oxide yellow.

7. ~~A~~ The soild tablet according to any of claims 1 to 6, characterised in that the pH adjuster is selected from the group consisting of tartaric acid, maleic acid and sodium citrate dihydrate.

8. ~~A~~ The solid tablet according to any of claims 1 to 7, characterised in that the flow regulator is selected from the group consisting of talc, anhydrous silicon dioxide and a lubricant.

9. ~~A~~ The solid tablet according to any of claims 1 to 8, characterised in that the lubricant is selected from the group consisting of macrogols (= polyethylene glycols), stearic acid, aluminium stearate, calcium arachinate and magnesium stearate.

10. ~~A~~ The soild tablet according to any of claims 1 to 9, comprising 0.5 to 5 mg of meloxicam and a tablet weight of 500 mg to 2000mg.

~~11. A tablet according to claim 10, comprising 1 to 4 mg, 1 to 3 mg, 1.5 to 2.5 mg or 1 to 2.5 mg of meloxicam.~~

~~12~~11. ~~A~~ The soild tablet according to any of claims 1 to ~~11~~10, comprising a flavour in an amount of 2 to 15% by weight of the total tablet weight.

~~13~~12. ~~A~~ The soild tablet according to any of claims 1 to ~~12~~11, characterised in that the flavour is an artificial beef flavour.

~~14~~13. ~~A~~ The soild tablet according to any of claims 1 to ~~13~~12, characterised in that the solid formulation contains meloxicam as a free base.

~~15~~14. A direct compression process without any granulation step, comprising the following steps:

1) Premixing of meloxicam with 10 – 50% of a filler/disintegrant followed by screening through a suitable mesh having a mesh size of 600 µm to 1500 µm;
2) Premixing of a pH adjuster and one or more colouring agents followed by screening through a suitable mesh having a mesh size of 600 µm to 1500 µm;
3) Mixing of 90-50% of a filler/disintegrant, a second filler/disintegrant, flow regulator, lubricant and artificial flavour followed by screening through a mesh having a mesh size of 600 µm to 1500 µm;
4) Admixing the blends obtained in steps 1) and 2) followed by screening through a suitable mesh having a mesh size of 600 µm to 1500 µm;
5) Final blending of the mixtures obtained in steps 3) and 4) followed by screening through a suitable mesh having a mesh size of 600 µm to 1500 µm;
6) Compression of the powder mixture obtained in step 5) into a tablet, wherein the tablet can be broken into two, three and/or four units with each unit containing equal amounts of the active ingredient.

~~16~~15. ~~A~~ The direct compression process without any granulation step according to claim ~~15~~14, wherein the steps comprise:

1) Premixing of meloxicam with 33% of a filler/disintegrant followed by screening through a suitable mesh having a mesh size of 600 µm to 1500 µm;
2) Premixing of a pH adjuster and one or more colouring agent followed by screening through a suitable mesh having a mesh size of 600 µm to 1500 µm;
3) Mixing of 67% of a filler/disintegrant, a second filler/disintegrant, flow regulator, lubricant and an artificial flavour followed by screening through a suitable mesh having a mesh size of 600 µm to 1500 µm;
4) Admixing the blends obtained in steps 1) and 2) followed by screening through a suitable mesh having a mesh size of 600 µm to 1500 µm;
5) Final blending of the mixture obtained in steps 3) and 4) followed by screening through a suitable mesh having a mesh size of 600 µm to 1500 µm;
6) Compression of the powder mixture obtained in step 5) into a tablet, wherein the tablet can be broken into two, three and/or four units with each unit containing equal amounts of the active ingredient.

~~17~~16. A solid tablet comprising meloxicam or a pharmaceutically acceptable salt thereof, wherein the solid tablet is obtainable by the direct compression process without any granulation step according to claim ~~15~~ 14 or ~~16~~15, wherein the tablet comprises directly-compressed powder screened through a suitable mesh having a mesh size of 600 µm to 1500 µm and contains meloxicam particles with a particle size of equal to and less than the selected mesh size ~~have a diameter ranging from 10 mm to 20 mm and a height ranging from 5 mm to 7mm, wherein meloxicam is homogenously dispersed within the tablet,~~ and wherein the tablet can be broken into two, three and/or four units with each unit containing equal amounts of the active ingredient.